Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2013

View Archived Issues

Boehringer Ingelheim patents new CCR2 receptor antagonists

Scientists elucidate factors necessary for platelet killing of P. falciparum

Takeda provides overview of activities from April-December 2012

Immune responses analyzed in infants administered an enterovirus vaccine

Bristol-Myers Squibb patents new Y4 receptor agonists

New PI3Kgamma and delta inhibitors disclosed by Infinity Pharmaceuticals and Intellikine

Scientists at Theracrine patent novel agents for cancer

Laboratorios del Dr. Esteve synthesizes novel sigma1-receptor ligands

Nanjing Molecular Research divulges new agents for HCV infection

GlaxoSmithKline: fourth quarter 2012 in review

First-in-human results of LNP-encapsulated siRNA therapy show promise in cancer patients

Albany Molecular Research out-licenses tubulin inhibitor

Champions Oncology receives on-time payment under Teva technology collaboration

TG Therapeutics opens expansion cohorts in trial of ublituximab

Catabasis Pharmaceuticals reports phase I data for CAT-1004

Synageva BioPharma begins phase III ARISE trial

UCB and Amgen decide not to pursue romosozumab program in fracture healing

Galenica provides update on regulatory processes for PA-21

Pediatric indication of Ixiaro approved in Europe

French group synthesizes new imino-sugar derivatives

Pfizer presents new GPR119 receptor agonists

Merck KGaA synthesizes novel FSH receptor agonists

Revlimid approved in China, gets priority review for new indication in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...